Evidence map›Paper›PMID 35982675›Full record

ArticleResearch square2022

A Randomized Trial of Lipid Metabolism Modulation with Fenofibrate for Acute Coronavirus Disease 2019.

Julio Chirinos, Patricio Lopez-Jaramillo, Evangelos Giamarellos-Bourboulis, Gonzalo Dávila-Del-Carpio, Abdul Bizri, Jaime Andrade-Villanueva, Oday Salman, Carlos Cure-Cure, Nelson Rosado-Santander, Mario Cornejo Giraldo and 36 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

46 authors at 20 institutions in 9 countries.

Julio ChirinosUniversity of Pennsylvania.
Patricio Lopez-JaramilloUniversidad de Santander.
Evangelos Giamarellos-BourboulisNational and Kapodistrian University of Athens.
Gonzalo Dávila-Del-CarpioUniversidad Católica de Santa María.
Abdul BizriAmerican University of Beirut.
Jaime Andrade-VillanuevaHospital Civil de Guadalajara and Universidad de Guadalajara.
Oday SalmanHospital of the University of Pennsylvania and Perelman School of Medicine, American University of Beirut.
Carlos Cure-CureBIOMELAB S.A.S.
Nelson Rosado-SantanderHospital Nacional Carlos Alberto Seguín Escobedo.
Mario Cornejo GiraldoHospital Carlos Alberto Seguín Escobedo.
Luz González-HernándezHospital Civil de Guadalajara and Universidad de Guadalajara.
Rima MoghniehMakassed General Hospital.
Rapti AngelikiSOTIRIA Athens General Hospital of Chest Disease.
María Cruz SaldarriagaHospital Nacional Adolfo Guevara Velasco.
Marcos ParionaHospital Nacional Edgardo Rebagliati Martins.
Carola MedinaHospital Nacional Edgardo Rebagliati Martins.
Ioannis DimitroulisSOTIRIA Athens General Hospital of Chest Disease.
Charalambos VlachopoulosNational and Kapodistrian University of Athens.
Corina GutierrezBIOMELAB S.A.S.
Juan Rodriguez-MoriHospital Nacional Alberto Sabogal Sologuren.
Edgar Gomez-LaitonFOSCAL Internacional Floridablanca.
Rosa PereyraHospital Nacional Guillermo Almenara Irigoyen.
Jorge Ravelo HernándezHospital Central Fuerza Aérea del Perú.
Hugo ArbañilHospital Nacional Dos de Mayo.
José Accini-MendozaIPS Centro Científico Asistencial.
Maritza Pérez-MayorgaClínica de Marly.
Haralampos MilionisSchool Of Medicine, University Of Ioannina, Ioannina, Greece.ORCID 0000-0003-3958-2266
Garyfallia PoulakouNational and Kapodistrian University of Athens.
Gregorio SánchezFundación Cardiomet Cequin.
Renzo Valdivia-VegaHospital Nacional Edgardo Rebagliati Martins.ORCID 0000-0002-8718-4361
Mirko Villavicencio-CarranzaHospital Nacional Edgardo Rebagliati Martins.
Ricardo Ayala-GarciaHOSPITAL NACIONAL EDGARDO REBAGLIATI MARTINS.ORCID 0000-0002-7913-8728
Carlos Castro-CallirgosHospital Nacional Alberto Sabogal Sologuren.
Rosa Alfaro CarrascoHospital Nacional Adolfo Guevara Velasco CUZCO.
Willy Lecca DanosHospital Nacional Adolfo Guevara Velasco CUZCO.
Tiffany SharkoskiHospital of the University of Pennsylvania and Perelman School of Medicine.
Katherine GreeneHospital of the University of Pennsylvania and Perelman School of Medicine.
Bianca PourmussaHospital of the University of Pennsylvania and Perelman School of Medicine.
Candy GreczyloHospital of the University of Pennsylvania and Perelman School of Medicine.
Jesse ChittamsUniversity of Pennsylvania School of Nursing.
Paraskevi KatsaounouNational and Kapodistrian University of Athens.
Zoi AlexiouTHRIASIO Eleusis General Hospital.
Styliani SympardiTHRIASIO Eleusis General Hospital.
Nancy SweitzerWashington University School of Medicine.
Mary PuttPerelman School of Medicine. University of Pennsylvania.
Jordana CohenUniversity of Pennsylvania.
Hospital of the University of Pennsylvania · USSt Martins Hospital · GBNational and Kapodistrian University of Athens · GRSotiria General Hospital · GRUniversidad de Guadalajara · MXUniversity of Pennsylvania · USAmerican University · USAmerican University of Beirut · LBCalifornia University of Pennsylvania · USCatholic University of Santa María · PEChilean Air Force · CLFoscal Hospital · COHospital Base Guillermo Almenara Irigoyen · PEHospital Nacional Cayetano Heredia · PEHospital Nacional Dos de Mayo · PEInstituto de Investigaciones Científicas y Servicios de Alta Tecnología · PAMakassed General Hospital · LBThriasio General Hospital of Elefsina · GRUniversidad de Santander · PAUniversity of Ioannina · GR

Funding

Efficacy of Fenofibrate for COVID-19: A phase II randomized controlled trialU01TR003734 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI CHIRINOS MEDINA, JULIO ALONSO · 2021 to 2021
$1.8M
NCATS NIH HHS U01 TR003734
6 · The paper itself

Abstract

Background Abnormal cellular lipid metabolism appears to underlie SARS-CoV-2 cytotoxicity and may involve inhibition of peroxisome proliferator activated receptor alpha (PPARα). Fenofibrate, a PPAR-α activator, modulates cellular lipid metabolism. Fenofibric acid has also been shown to affect the dimerization of angiotensin-converting enzyme 2, the cellular receptor for SARS-CoV-2. Fenofibrate and fenofibric acid have been shown to inhibit SARS-CoV-2 replication in cell culture systems

Identifiers

PMID35982675
PMCPMC9387540
OpenAlexW4290988286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.